NRC

NRC (National Research Corporation) Analyst Note Date: 2026-06-13 Subject: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

Current Price: $18.54 Conservative Entry: — (Not yet actionable; requires confirmed breakout) Aggressive Entry: $17.24 (Pre-breakout / forming entry) Breakout Level: $22.79 (Resistance level that must be cleared to confirm the setup) Extension: — (Price is currently within the base structure, not extended)

Classification: The setup is classified as FORMING.

• Volatility Context: The current ATR is 5.9%, which falls into the "high" bucket (historical sweet spot of 4–6%). This suggests sufficient volatility to support a move, but also implies wider stop-loss requirements compared to low-volatility names.

2. Thesis Layer

Thesis Status: TACTICAL / Setup-Led Macro Thesis: None. There is no named secular thesis attached to NRC at this date. The investment case is strictly setup-led, relying on the quality of the technical structure (the Coil) combined with the underlying business fundamentals. We do not invent a macro narrative; we judge this name on the strength of its recurring revenue growth, margin inflection potential, and the structural readiness of the price action.

3. The Business

Company Overview: National Research Corporation (NRC) operates in the Healthcare sector, providing subscription-based solutions and market intelligence to healthcare organizations. The company's portfolio focuses on mission-critical constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.

Business Model & Evidence (as of 2026-06-13): NRC operates on a recurring revenue model driven by Total Recurring Contract Value (TRCV). Management has highlighted a strategic shift toward a selling approach that mirrors healthcare system decision-making, resulting in significant growth in new sales and retention.

• Recurring Revenue Growth: As of the February 3, 2026 earnings transcript, TRCV reached $144 million, marking an 8% year-over-year increase and the fifth consecutive quarter of sequential growth. By March 31, 2026, TRCV had risen to $152.0 million (an all-time high), driven by sales to new and existing customers and improved retention (Evidence E1, E9, E14).
• Sales Momentum: Full-year new sales increased 86% year-over-year in 2025, attributed to a refined selling approach (Evidence E2).
• Retention Quality: The company achieved its highest gross dollar retention rate in over 7 years (Evidence E3).
• Product Expansion: The "Rounding" product line gained strong momentum, with TRCV nearly doubling in 2025 (Evidence E4).
• Market Penetration: NRC serves 74% of the top 100 health systems in the country, leveraging brand trust to secure scale (Evidence E5).
• Backlog Visibility: As of March 31, 2026, total remaining contract revenue for contracts with original durations greater than one year was approximately $194.5 million, with $61.5 million expected to be recognized in the next 12 months (Evidence E8).
• Financial Guidance: Management expects revenue, operating margin, and operating cash flow to grow in 2026, citing TRCV growth and a lower expense run rate (Evidence E15).

4. Archetype and Conviction Stack

Archetype: Margin Inflector Rationale: NRC fits the "Margin Inflector" archetype. The company is demonstrating a transition from high-growth sales to improved profitability through:

• Improved Retention: The highest gross dollar retention rate in 7 years (Evidence E3) reduces churn costs and stabilizes the revenue base.
• Expense Optimization: Management explicitly notes a "lower expense run rate" and improved revenue per associate (Evidence E15, E16).
• Non-Recurring Adjustments: While there are one-time expenses related to management changes and equity acceleration ($9.4 million in Q2 2026), these are expected to clear the path for future margin expansion (Evidence E12).

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro tailwinds).
• Evidence Quality: High. The evidence base is robust, with consistent TRCV growth, high retention rates, and clear visibility into future revenue ($194.5M backlog).
• Setup Readiness: Partial. The coil is "forming," meaning it has not yet fired. It requires a close above $22.79 to become a confirmed setup.
• Rerating Potential: Moderate. The combination of 86% new sales growth and margin inflection could support a multiple expansion if the breakout confirms.

Valuation Context: Forward consensus EPS is estimated at $0.88 for FY1 and $1.11 for FY2 (Evidence E29). The current price of $18.54 implies a forward P/E of approximately 21x for FY1. Given the high growth in new sales and the inflection in margins, this valuation appears reasonable for a company with a 74% penetration of top health systems, provided the breakout occurs.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A significant decline in TRCV or a drop in the gross dollar retention rate below the 7-year high levels reported in early 2026.
• Operational: Failure to recognize the $61.5 million in backlog revenue over the next 12 months, or a reversal of the "lower expense run rate" trend.

What Would Strengthen the Case:

• Technical: A confirmed close above the breakout level of $22.79.
• Fundamental: Continued sequential growth in TRCV beyond the $152.0 million peak reported in March 2026.
• Operational: Confirmation that the $9.4 million in Q2 2026 expenses are non-recurring and that operating margins expand as management expects.

Gaps in Evidence:

• Specific Margin Metrics: While management expects margin growth, specific historical operating margin percentages for 2025 and the exact target for 2026 are not detailed in the provided evidence.
• Customer Concentration: While 74% of top 100 systems are served, the revenue concentration by individual customer is not disclosed.
• Competitive Landscape: No specific data on competitor pricing or market share shifts is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: Setup is not yet confirmed (price below breakout level of $22.79); High current ATR (5.9%) increases volatility risk; One-time $9.4 million expense in Q2 2026 may impact near-term earnings; No named secular thesis to provide macro tailwinds. Sizing hint: Position size should be conservative relative to a confirmed breakout, reflecting the partial readiness of the forming coil. Expected path: Management expects revenue, operating margin, and operating cash flow to grow in 2026 as TRCV growth translates to top-line results and expense run rates normalize. Expected horizon: 3 to 6 months for the technical setup to resolve (breakout or invalidation).